Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Earthquake Impact on Active Margins: Tracing Surficial Remobilization and Seismic Strengthening in a Slope Sedimentary Sequence.

Molenaar A, Moernaut J, Wiemer G, Dubois N, Strasser M.

Geophys Res Lett. 2019 Jun 16;46(11):6015-6023. doi: 10.1029/2019GL082350. Epub 2019 Jun 12.

2.

Megathrust earthquake drives drastic organic carbon supply to the hadal trench.

Kioka A, Schwestermann T, Moernaut J, Ikehara K, Kanamatsu T, McHugh CM, Dos Santos Ferreira C, Wiemer G, Haghipour N, Kopf AJ, Eglinton TI, Strasser M.

Sci Rep. 2019 Feb 7;9(1):1553. doi: 10.1038/s41598-019-38834-x.

3.

Restoration of endothelial function via enhanced nitric oxide synthesis after long-term treatment of raloxifene in adult hypertensive rats.

Leitzbach D, Weckler N, Madajka M, Malinski T, Wiemer G, Linz W.

Arzneimittelforschung. 2005;55(2):86-92.

PMID:
15787275
4.

Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.

Linz W, Itter G, Dobrucki LW, Malinski T, Wiemer G.

J Renin Angiotensin Aldosterone Syst. 2003 Sep;4(3):180-5.

PMID:
14608524
5.

Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Hropot M, Langer KH, Wiemer G, Grötsch H, Linz W.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Mar;367(3):312-7. Epub 2003 Jan 25.

PMID:
12644905
6.

AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium.

Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H.

Hypertension. 2002 Dec;40(6):847-52.

PMID:
12468568
7.

Decreased nitric oxide availability in normotensive and hypertensive rats with failing hearts after myocardial infarction.

Wiemer G, Itter G, Malinski T, Linz W.

Hypertension. 2001 Dec 1;38(6):1367-71.

PMID:
11751719
8.

Tissue kallikrein KLK1 is expressed de novo in endothelial cells and mediates relaxation of human umbilical veins.

Dedio J, Wiemer G, Rütten H, Dendorfer A, Schölkens BA, Müller-Esterl W, Wohlfart P.

Biol Chem. 2001 Oct;382(10):1483-90.

PMID:
11727832
9.

Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells.

Heitsch H, Brovkovych S, Malinski T, Wiemer G.

Hypertension. 2001 Jan;37(1):72-76.

PMID:
11208759
10.

Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats.

Linz W, Heitsch H, Schölkens BA, Wiemer G.

Hypertension. 2000 Apr;35(4):908-13.

PMID:
10775560
11.

Ischemic preconditioning and infarct mass: the effect of hypercholesterolemia and endothelial dysfunction.

Jung O, Jung W, Malinski T, Wiemer G, Schoelkens BA, Linz W.

Clin Exp Hypertens. 2000 Feb;22(2):165-79.

PMID:
10744357
12.

Interactions among ACE, kinins and NO.

Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G.

Cardiovasc Res. 1999 Aug 15;43(3):549-61. Review. No abstract available.

PMID:
10690327
13.

Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.

Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, Strobel H, Wiemer G.

Br J Pharmacol. 1999 Nov;128(6):1316-22.

14.

Amyloid beta-(1-40) stimulates cyclic GMP production via release of kinins in primary cultured endothelial cells.

Wirth KJ, Fink E, Rudolphi K, Heitsch H, Deutschländer N, Wiemer G.

Eur J Pharmacol. 1999 Oct 1;382(1):27-33.

PMID:
10556501
15.

Late treatment with ramipril increases survival in old spontaneously hypertensive rats.

Linz W, Wohlfart P, Schoelkens BA, Becker RH, Malinski T, Wiemer G.

Hypertension. 1999 Aug;34(2):291-5.

PMID:
10454456
16.

Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats.

Zimmermann R, Kastens J, Linz W, Wiemer G, Schölkens BA, Schaper J.

J Mol Cell Cardiol. 1999 Aug;31(8):1447-56.

PMID:
10423343
17.

Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.

Linz W, Becker RH, Schölkens BA, Wiemer G, Keil M, Langer KH.

Kidney Int. 1998 Dec;54(6):2037-44.

18.
19.

Long-term ACE inhibition doubles lifespan of hypertensive rats.

Linz W, Jessen T, Becker RH, Schölkens BA, Wiemer G.

Circulation. 1997 Nov 4;96(9):3164-72.

PMID:
9386189
20.

Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats.

Wiemer G, Linz W, Hatrik S, Schölkens BA, Malinski T.

Hypertension. 1997 Nov;30(5):1183-90.

PMID:
9369274
21.

Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production.

Bouloumié A, Bauersachs J, Linz W, Schölkens BA, Wiemer G, Fleming I, Busse R.

Hypertension. 1997 Oct;30(4):934-41.

PMID:
9336396
22.

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size.

Linz W, Wiemer G, Schölkens BA.

Am J Cardiol. 1997 Aug 4;80(3A):118A-123A. Review.

PMID:
9293964
23.

Kinins and cardioprotection.

Wirth KJ, Linz W, Wiemer G, Schölkens BA.

Pharmacol Res. 1997 Jun;35(6):527-30. Review.

PMID:
9356203
24.

Different B1 kinin receptor expression and pharmacology in endothelial cells of different origins and species.

Wohlfart P, Dedio J, Wirth K, Schölkens BA, Wiemer G.

J Pharmacol Exp Ther. 1997 Feb;280(2):1109-16.

PMID:
9023330
25.

Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats.

Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T.

Hypertension. 1996 Sep;28(3):397-402.

PMID:
8794823
26.

ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.

Linz W, Wiemer G, Schmidts HL, Ulmer W, Ruppert D, Schölkens BA.

Clin Exp Hypertens. 1996 Jul;18(5):691-712.

PMID:
8781754
27.

Differences in acetylcholine- and bradykinin-induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages.

Wirth KJ, Linz W, Wiemer G, Schölkens BA.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Jun;354(1):38-43.

PMID:
8832586
28.

Role of kinins in myocardial ischemia.

Linz W, Martorana PA, Wiemer G, Wirth K, Schölkens BA.

EXS. 1996;76:231-41. Review. No abstract available.

PMID:
8805798
29.

Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.

Linz W, Wiemer G, Schölkens BA.

Diabetes. 1996 Jan;45 Suppl 1:S51-8. Review.

PMID:
8529801
30.

Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.

Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, Unger T, Schölkens BA.

Mol Cell Biochem. 1995 Jun 7-21;147(1-2):89-97. Review.

PMID:
7494560
31.

Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA.

Pharmacol Rev. 1995 Mar;47(1):25-49. Review.

PMID:
7784479
32.

The bradykinin B2 receptor antagonist WIN 64338 inhibits the effect of des-Arg9-bradykinin in endothelial cells.

Wirth KJ, Schölkens BA, Wiemer G.

Eur J Pharmacol. 1994 Dec 15;288(1):R1-2.

PMID:
7705460
33.

Furosemide enhances the release of endothelial kinins, nitric oxide and prostacyclin.

Wiemer G, Fink E, Linz W, Hropot M, Schölkens BE, Wohlfart P.

J Pharmacol Exp Ther. 1994 Dec;271(3):1611-5.

PMID:
7996475
34.

Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.

Hropot M, Grötsch H, Klaus E, Langer KH, Linz W, Wiemer G, Schölkens BA.

Naunyn Schmiedebergs Arch Pharmacol. 1994 Dec;350(6):646-52.

PMID:
7535899
35.

Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.

Linz W, Wiemer G, Schölkens BA.

Braz J Med Biol Res. 1994 Aug;27(8):1949-54.

PMID:
7749386
36.

Effect of chronic high- and low-dose ACE inhibitor treatment on cardiac and vascular hypertrophy and vascular function in spontaneously hypertensive rats.

Gohlke P, Linz W, Schölkens BA, Wiemer G, Martorana P, Van Even P, Unger T.

Exp Nephrol. 1994 Mar-Apr;2(2):93. No abstract available.

PMID:
8082021
37.
38.

Endothelial protection by converting enzyme inhibitors.

Wiemer G, Schölkens BA, Linz W.

Cardiovasc Res. 1994 Feb;28(2):166-72. Review. No abstract available.

PMID:
8143296
39.

[Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].

Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA.

Z Kardiol. 1994;83 Suppl 4:53-6. Review. German.

PMID:
7856280
40.

The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts.

Wiemer G, Schölkens BA, Wagner A, Heitsch H, Linz W.

J Hypertens Suppl. 1993 Dec;11(5):S234-5. No abstract available.

PMID:
8158361
41.

Bradykinin prevents left ventricular hypertrophy in rats.

Linz W, Wiemer G, Schölkens BA.

J Hypertens Suppl. 1993 Dec;11(5):S96-7. No abstract available.

PMID:
7512641
42.

Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.

Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Linz W, Schölkens BA, Wiemer G, Unger T.

Hypertension. 1993 Nov;22(5):682-7.

PMID:
8225528
43.

Ramiprilat increases bradykinin outflow from isolated hearts of rat.

Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G.

Br J Pharmacol. 1993 Feb;108(2):293-5.

44.

Contribution of bradykinin to the cardiovascular effects of ramipril.

Linz W, Wiemer G, Schölkens BA.

J Cardiovasc Pharmacol. 1993;22 Suppl 9:S1-8. Review.

PMID:
7514234
45.
46.

ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.

Linz W, Wiemer G, Schölkens BA.

J Mol Cell Cardiol. 1992 Aug;24(8):909-19.

PMID:
1331474
47.
48.

Effects of converting enzyme inhibitors and the calcium antagonist nifedipine alone and in combination on precontracted isolated rabbit aortic rings.

Wiemer G, Becker RH, Jablonka B, Rosenkranz G, Schölkens BA, Linz W.

Arzneimittelforschung. 1992 Jun;42(6):795-7.

PMID:
1329777
50.

DesArg10[Hoe 140] is a potent B1 bradykinin antagonist.

Wirth KJ, Wiemer G, Schölkens BA.

Agents Actions Suppl. 1992;38 ( Pt 2):406-13.

PMID:
1334341

Supplemental Content

Loading ...
Support Center